An alternative, complementary approach is to study the genetic liability for OUD across different stages, particularly the transition from use to misuse. By taking this approach, we can explore specific aspects of OUD liability, such as initial use, subjective drug response, transition to hazardous use, dependence, withdrawal, and relapse. This strategy can be applied in population-based cohorts, allowing for a dramatic increase in sample sizes for a fraction of the cost.
